P/E ratio for Verastem Oncology (VSTM)
P/E ratio as of May 2024 (TTM): -2.49
According to Verastem Oncology 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.49428. At the end of 2022 the company had a P/E ratio of -1.06.
P/E ratio history for Verastem Oncology from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.06 | -78.81% |
| 2021 | -5.00 | 24.41% |
| 2020 | -4.02 | 502.83% |
| 2019 | -0.6667 | -77.58% |
| 2018 | -2.97 | 69.5% |
| 2017 | -1.75 | 53.5% |
| 2016 | -1.14 | -0.46% |
| 2015 | -1.15 | -74% |
| 2014 | -4.42 | -29.51% |
| 2013 | -6.26 | 21.14% |
| 2012 | -5.17 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 15.0 | -699.44% | 🇺🇸 USA |
 LabCorp LH | 26.8 | -1,173.31% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 12.4 | -598.18% | 🇬🇧 UK |
 Curis CRIS | -1.64 | -34.41% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.